Effective regulation of contents of tobacco products is one of the primary milestones to reduce negative health effects associated with the use of smokeless tobacco (SLT) products. As per the available sources, testing of some SLT products has been done on ad hoc basis, but there is a lack of comprehensive and periodic analysis of these products. In addition, the available results indicate huge variations among the levels of pH, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, N-nitrosonornicotine, benzo[a]pyrene, heavy metals and nicotine within different products as well as within different brands of the same product. This review was aimed to throw light on the variations and gaps in testing of SLT products and emphasize the need for strong policy regulation for monitoring the chemical constituents of these products.
Introduction
Smokeless tobacco (SLT), a non-combustible form of tobacco, is consumed by 350 million people in 133 countries across the globe 1 . As per a recent survey, SLT use accounts to approximately 0.65 million deaths annually 1 . Consumption of these products has been reported to be associated with many diseases such as cancers, neurological disorders and oral and heart diseases 2, 3 . This can be attributed to the presence of harmful chemicals along with 28 known carcinogens [4] [5] [6] [7] [8] [9] [10] .
While there are regulations on the concentrations of chemicals in other commercially available products such as pesticides, medicines and food additives, no such policies are available for SLT products. Considering tobacco products, a lot of efforts have been employed for regulation of chemical contents of cigarette and cigarette smoke. One such effort includes mandating validation methods for testing of chemical constituents of cigarette 11 . International Organization for Standardization has been actively involved in the development of standards related to testing of cigarette smoke. Their technical committee has developed 64 international standards related to testing of tobacco and tobacco products, especially smoke 11 . However, majority of efforts are
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concentrated towards the regulation of cigarettes and cigarette smoke. In spite of many evidences on the hazardous effect of SLT products on humans, not much emphasis has been given on their regulation. Thus, there is a strong need for comprehensive identification and characterization of the toxic contents through analytical testing and extensive research about potential health hazards of these products. This type of analytical testing will help to establish a correlation between products, chemical constituents and their short-term and long-term toxicological effects on the organs and tissues.
Articles 9 and 10 of World Health Organization (WHO) Framework Convention on Tobacco Control (FCTC) call for regulation of the contents and disclosures of tobacco products. According to Global Progress Report on SLT, 2016, from FCTC, the average implementation rate of Article 9 was around 50 per cent and that comprised mostly for smoking 12, 13 . Hence, the first step for regulation of SLT products has been taken up by the WHO FCTC focusing on implementation of Article 9 for regulation of SLT products 14 .
This review focuses on information on testing of SLT constituents, their regulation and challenges. It showcases the discrepancies and gaps in the regulation of toxic contents of SLT products highlighting country-wise and brand-wise differences in the previously tested samples. It also emphasizes the need for stringent policy regulations and their strong implementation for monitoring the chemical constituents of these products.
Carcinogens in smokeless tobacco products
SLT products contain a diversity of chemical compounds belonging to a variety of different classes such as organic tobacco-specific nitrosamines (TSNAs), polyaromatic hydrocarbons, inorganic metals and salts. TSNAs contain known potent carcinogens such as N-nitrosonornicotine (NNN), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N-nitrosoanabasine (NAB). Volatile N-nitrosamines contain N-nitrosodimethylamine, N-nitrosopyrrolidine, N-nitrosopiperidine, N-nitrosomorpholine and N-nitrosodiethanolamine. Table I 15 . TSNAs are formed from tobacco alkaloids in the presence of nitrates as explained below.
Role of nicotine and its conversion to tobacco-specific nitrosamines (TSNAs)
Tobacco plant contains four major alkaloids namely nicotine, nornicotine, anabasine and anatabine. Nicotine is the primary alkaloid and constitutes a major proportion (90-95%) of all alkaloid pools present in the commercially used tobacco plants 16 . It can undergo demethylation to form nornicotine, anabasine and anatabine. TSNAs (NNN, NNK, NAT and NAB) are formed by nitrosation of these alkaloids during curing and processing of tobacco products. NNN, NNK, NAT and NAB are known carcinogens and are found to be associated with oral, oesophageal and pancreatic cancers 17, 18 .
Variation in tobacco-specific nitrosamines (TSNAs) and benzo[a]pyrene (B[a]P)
Compiling all the published articles in Table II , there is a wide variation in the levels of TSNAs across different countries and across different brands within a country. There is a 60-fold variation (0.66-42.5 µg/g) in NNN content of moist snuff in USA, while for dry snuff, the variation is 100 folds (0.8-81.3 µg/g). Wide variations in the amount of other TSNAs are also observed. NNK content of most of the products in USA varies from 0.05 µg/g in dissolvables to 20.3 µg/g in dry snuff. In SLT products manufactured in India, NNN varies from 0.09 µg/g in gutka to 40 µg/g in khaini, while NNK varies from 0.04 µg/g in gutka to 24.1 µg/g in zarda.
Globally, variations in NNN range from 0.01 µg/g (rapé from Brazil)) to 3085 µg/g (toombak from Sudan) 47 , NNK varies from 0.004 µg/g (rapé from Brazil and mawa from Pakistan) to 7870 µg/g (toombak from Sudan) 47 , NAT from 0.006 µg/g to 170 µg/g (moist snuff in Canada) and NAB from 0.001 µg/g (rapé in Brazil) to 4.8 µg/g (moist snuff in Canada). Variation of another potent Group 1 carcinogen, B[a]P ranges from 0 ng/g (snus in USA) to 104 ng/g in Iq'mik in USA (Table III) . Such wide variations in the concentration of toxicants are influenced by various factors such as tobacco plant, tobacco type, nitrate and alkaloid content, method of cultivation, pesticides used, harvesting and processing techniques and storage conditions. As per a report, extremely high levels of TSNAs in Sudanese toombak have been attributed to high levels of tobacco alkaloids in Nicotiana rustica 7 .
Variation of heavy metals in smokeless tobacco products
A variety of toxic metals such as arsenic, cadmium, chromium, lead and nickel have also been identified. These are either absorbed by the tobacco plant from 48 . It has been previously studied that toxicity of heavy metals has a direct correlation with the burden of metals in our body. Therefore, change in their concentration by consumption of SLT leads to severe toxicity 49 . Some other diseases include diseases of bone and kidney (excess of cadmium), neurological disorders (excess of lead) 50, 51 and metabolic disorders (excess of zinc and copper) 52, 53 . Table III indicates the amounts of metals in different SLT products tested worldwide.
Only a few countries listed in Table III have tested their SLT products for estimation of metal contents. It is also important to note that all these reports are published one time by individual research groups following no standard operational procedures. Since there is no government agency involved, periodic testing and monitoring does not take place. For instance, Houas et al 55 compared the mineral concentrations of SLT, water pipe tobacco and cigarettes from the Tunisian Market, while Brima 62 estimated the concentration of metal level in Shamma, found in Saudi Arabia. Table IV indicates different standards for testing of SLT products. Tables III and IV , concentration of arsenic, lead and chromium in some of the SLT products from Pakistan (Naswar) was found to be 50 times more than GOTHIATEK ® limits 57 . Nickel concentration in Shamma, a SLT product found in Saudi Arabia, was 118 times greater than GOTHIATEK® limits 62 . In India, lead content in one of the brands of gutka was found to be 68 times greater than the defined limit 54 . In general, there was a large variation in concentration in most of the metals, which was much more than the acceptable limits.
According to

Variation in pH and its effect on nicotine absorption
Nicotine content of a SLT product is the primary determinant of cause of addiction among users. The unprotonated form of nicotine or 'free nicotine' is easily absorbed by the oral mucosa 66 . Absorption of nicotine at the buccal surface is governed by the pH of SLT product 67 . Higher pH facilitates more absorption and vice versa. At low pH, nicotine gets ionized and is thus unable to cross biological membranes 67 .
Table V depicts wide variations in the pH levels of various SLT products. As an example, the level of pH ranges from as low as is from 5.1 mg/g in Brazilian rapѐ to 10.2 mg/g in Swedish snus and Brazilian rapé. Variation in free nicotine content is from 0.01 mg/g in the USA moist snuff to 65 mg/g in Indian zarda. 
Regulation of tobacco products
Given the huge variation in the toxic contents of currently available SLT products, it becomes extremely imperative to consider the acceptable levels of harm. According to Gray and Borland 70 , there are three major regulatory possibilities for tobacco: (i) regulation of carcinogens and toxins such as TNSAs, B[a]P and metals; (ii) regulation of nicotine for addictiveness, and (iii) regulation of additives. Considering the wide variations in chemical content and lack of monitoring agencies, there is an immediate need to develop validated methods for estimating the toxicity/carcinogenicity of SLT products 70 .
Two of the widely used standards are TobReg 64 and GOTHIATEK® 65 . Tobacco Product Regulation (TobReg) group of WHO has set the maximum acceptable limit of NNN+NNK to ≤2 μg/g dry weight of tobacco and B[a]P to 5 ng/g dry weight of tobacco (Table IV) . Swedish Match has published standards for maximum allowable levels of TSNAs, metals and trace elements, which are collectively known as GOTHIATEK® standard 65 (Table IV) . Rickert et al 40 have stated in their report that some but not all experts on this topic have suggested that this standard is safe enough to be recommended by health authorities. GOTHIATEK® standard has been adopted by two big tobacco companies: British-American Tobacco and European Smokeless Tobacco Council (ESTOC) 71 .
Role of WHO FCTC
TobReg
The WHO established a tobacco-free initiative (TFI) in July 1998 to provide international attention to global tobacco epidemic. Its mandate is to reduce the global burden of disease and death caused by tobacco and thus working on a mission to protect the present and future generations from the consequences of tobacco consumption and exposure to tobacco smoke. TFI encompasses a Scientific Advisory Committee on Tobacco Product Regulation (SACTob) 72 whose aim is to provide scientific information and recommendation on tobacco product regulation related to Articles 9, 10 and 11 of the WHO FCTC. Most of the efforts regarding tobacco regulation have been done for cigarettes. TobReg has defined three models for cigarettes, each mentioning mandatory limits for emissions of nine different smoke toxicants 73 .
Tobacco Laboratory Network (TobLabNet)
As a step towards regulation, the WHO has established Tobacco Laboratory Network (TobLabNet) with the aim to regulate and provide testing and research of contents and emissions of tobacco products. Its major goal is to establish testing and research capacity of tobacco products for regulatory compliance. The report by WHO FCTC at the Conference of Parties 7 at New Delhi in November 2016 states that the already available WHO TobLabNet methods for analysis of TSNAs, B[a]P and nicotine can be adapted or applied to other SLT 74 . Furthermore, owing to the wide range of SLT products, there is a need to perform product-specific analysis in South Asia which is not presently performed by the TobLabNet due to lack of relevant laboratory expertise and/or capacity. The analytic procedures for metals, humectants, aldehydes and many other toxicants present in SLT need to be 
WHO Collaborating Centre on Tobacco Control
The WHO Collaborating Centre is a part of TFI whose aim is to form part of an international collaborative network carrying out activities on tobacco control and strengthen institutional capacity in countries and Regions. There are 16 WHO collaborating centres for tobacco control which work closely with TFI. Among these, six collaborating centres are working on tobacco testing and research (Table VI) . However, the laboratories of these centres focus on technical training on testing compounds and emissions of smoking products, especially cigarettes.
Effort at country level
India
India is the largest consumer of SLT products by number. Prevalence of SLT use among men and women is 29.6 and 12.8 per cent 75 , respectively. Although the burden is highest in India, not much effort except a few studies 76 
USA
Most of the testing procedures of SLT products around the world have been done in various laboratories of the USA (although the USA is not the signatories to the WHO FCTC). The Food and Drug Administration has proposed a rule that mean level of NNN in any batch of finished SLT products should not exceed 1.0 μg/g of tobacco on a dry weight basis 79 .
Europe
GOTHIATEK® standards have been accepted by ESTOC (a pan European SLT lobby) members and have become a voluntary standard for most of the SLT products manufactured in Europe 80, 81 . The United Kingdom has enforced regulation regarding tobacco products, especially cigarettes, which states that a person cannot produce, supply or manufacture for export of any cigarettes with emission level greater than 10 mg of tar/cigarette, 1 mg nicotine/cigarette and 10 mg of carbon monoxide/cigarette 82 .
Gaps
The available data indicate that very few laboratories, which are not funded by industry, are 
Conclusion
Although the toxicological and clinical risks associated with many of the SLT products are known, little effort has been taken to regulate their constituents. Considering the hazardous impact of SLT products on human health and wide prevalence among different parts of the world, there is an urgent need to pay more attention towards research on SLT products, their ingredients and emissions. More emphasis should be given on the establishment of tobacco testing laboratories in every region, which will be precisely the driving force behind the successful implementation of Articles 9 and 10 of WHO FCTC. In addition, major initiatives are required that promote collaborations between academia, researchers, scientists and governments to ensure that reports from the laboratory are quickly interpreted and efficiently translated for implementation. It will provide better avenues for researchers to find out newer ways of reducing hazardous compounds from tobacco products. This will in turn help governments to fund better research and help eradicate the problems associated with SLT. Another important step is to develop SOPs for testing of each toxic chemical compound of SLT products. These steps will help in the establishment of permissible upper limits of all chemical ingredients of SLT. And finally, the regulation will also reduce the burden on medical system which is catering to the affected individuals and will also help in strengthening economy worldwide. 
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